Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 11 to 20 of 1230

TitleReference numberPublishedLast updated
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancerTA1122
Acoramidis for treating transthyretin amyloidosis with cardiomyopathyTA1121
Suspected cancer: recognition and referralNG12
Avelumab with axitinib for untreated advanced renal cell carcinomaTA1120
Overweight and obesity managementNG246
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)TA1118
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTA1119
Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiencyTA1117
Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemiaTA1116
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathyTA1115

Results per page

  1. 10
  2. 25
  3. 50
  4. All